GLP-1 receptor agonists and cardiovascular protection: A class effect or not?

Affiliations

¹ Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU de Liège, Liège, Belgium; Clinical Pharmacology Unit, CHU Liège, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium. Electronic address: andre.scheen@chu.ulg.ac.be.

Editorial

André J Scheen. Diabetes Metab. 2018 Jun.

. 2018 Jun;44(3):193-196.

doi: 10.1016/j.diabet.2017.12.009. Epub 2018 Jan 6.

¹ Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU de Liège, Liège, Belgium; Clinical Pharmacology Unit, CHU Liège, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium. Electronic address: andre.scheen@chu.ulg.ac.be.

No abstract available

Keywords: Class-effect; GLP-1 receptor agonist.

Comment on

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group. Bethel MA, et al. Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. doi: 10.1016/S2213-8587(17)30412-6. Epub 2017 Dec 6. Lancet Diabetes Endocrinol. 2018. PMID: 29221659
Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer.
Dankner R, Freedman LS, Gerstein HC, Roth J, Keinan-Boker L. Dankner R, et al. Diabetes Metab Res Rev. 2018 Sep;34(6):e3018. doi: 10.1002/dmrr.3018. Epub 2018 Jun 17. Diabetes Metab Res Rev. 2018. PMID: 29673046